Compounds > soraprazan
Page last updated: 2024-12-08

soraprazan

Description

soraprazan: soraprazan and BYK61359 refer to the (7R,8R,9R)-isomer; a potassium-competitive acid blocker; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID213054
CHEMBL ID2105502
SCHEMBL ID1219146
MeSH IDM0511665

Synonyms (25)

Synonym
soraprazan
261944-46-1
(7r,8r,9r)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol
soraprazan [inn]
(7r,8r,9r)-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo(1,2-h)(1,7)naphtyridin-8-ol
byk-61359
byk61359
byk 61359
2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo(1,2-h)(1,7)naphthyridine
remofuscin
5xb3671655 ,
unii-5xb3671655
CHEMBL2105502
soraprazan [who-dd]
PWILYDZRJORZDR-MISYRCLQSA-N
(7r,8r,9r)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine
(7r,8r,9r)-8-hydroxy-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine
(7r,8r,9r)-2,3-dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine
SCHEMBL1219146
AKOS030604619
CS-7621
HY-100414
Q27263004
MS-25886
imidazo[1,2-h][1,7]naphthyridin-8-ol, 7,8,9,10-tetrahydro-7-(2-methoxyethoxy)-2,3-dimethyl-9-phenyl-, (7r,8r,9r)-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1910986Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A335V mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910992Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha L809F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910991Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910994Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha I816F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910984Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha V331F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910989Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799A mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910995Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha I816F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910993Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha L809F mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910980Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta subunit in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910988Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799A mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910982Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A123V mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910985Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A335V mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910981Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A123V mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910990Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha Y799F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910979Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A339S mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910983Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha V331F mutant/beta subunit activity in HEK293 cells by colorimetric microplate reader2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
AID1910987Ratio of IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha A339S mutant/beta subunit to IC50 for Inhibition of N-terminal Flag-GFP-TEV site-Met48 recombinant pig gastric H(+)/K(+) ATPase alpha/beta su2022Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11
Structural Basis for Binding of Potassium-Competitive Acid Blockers to the Gastric Proton Pump.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's3 (50.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.02 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index43.69 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
niacinamide
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.		2.0310pyridine alkaloid;
pyridinecarboxamide;
vitamin B3		anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor
nigericin
Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.		2.0310polycyclic etherantibacterial agent;
antimicrobial agent;
bacterial metabolite;
potassium ionophore
sch 28080
Sch 28080: not related structurally to other known anti-ulcer agents; inhibits histamine-stimulated gastric secretion; prevents gastric lesions induced by aspirin, indomethacin & ethanol		2.7630imidazopyridine
5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine
[no description available]		2.4110isoquinolines
s 1743
Esomeprazole: The S-isomer of omeprazole.. esomeprazole : A 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome.		2.0310magnesium saltanti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
dibutyl phthalate
6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-N-methyl-3-pyridinecarboxamide: GSK-189254 is the HCl salt; an H3 receptor antagonist; putative cognitive enhancer; structure in first source		2.0310
vonoprazan
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine: a proton pump inhibitor; structure in first source		2.4110pyrroles
ConditionIndicatedRelationship StrengthStudiesTrials
Fundus Flavimaculatus
[description not available]		02.2510
Age-Related Macular Degeneration
[description not available]		02.5320
Stargardt Disease
A juvenile-onset macular dystrophy characterized by progressive loss of VISUAL ACUITY with normal acuity in peripheral VISUAL FIELDS. Other associated clinical features may include LIPOFUSCIN fundus autofluorescence, atrophy of the RETINAL PIGMENT EPITHELIUM, loss of color vision, PHOTOPHOBIA and PARACENTRAL SCOTOMA. Germline mutations in the ABCA4 gene have been identified in recessive and dominant diseases.		02.2510
Macular Degeneration
Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.		02.5320
chemdatabank.com